Vivos Therapeutics, Inc.
VVOS
$2.14
$0.010.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.68% | 33.62% | -25.04% | 65.10% | -120.96% |
| Total Depreciation and Amortization | 21.23% | -3.36% | -2.01% | -2.03% | -16.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.02% | -86.40% | 109.43% | -80.45% | 113.32% |
| Change in Net Operating Assets | -153.12% | -135.21% | -361.43% | -254.05% | 244.21% |
| Cash from Operations | -50.87% | -6.99% | -49.54% | -6.61% | 28.91% |
| Capital Expenditure | 19.21% | 0.00% | -24.68% | 75.51% | 47.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 19.21% | 0.00% | -24.68% | 75.51% | 47.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -12.50% | -- | -- | -50.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -3.24% | -- | -- | 52.56% |
| Cash from Financing | -- | -14.41% | -- | -- | -50.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -504.75% | -107.79% | 79.96% | 238.27% | -72.55% |